Akute und chronische Herzinsuffizienz

Abstract

The initial therapy of chronic heart failure is still based on diuretics, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers and in specific cases mineralocorticoid receptor antagonists. The new European Society of Cardiology (ESC) guidelines published in 2016 introduced angiotensin-receptor-neprilysin inhibitors, such as sacubitril/valsartan (LCZ 696) as new therapeutic agents in patients with chronic and progressive heart failure. New subgroup analyses for LCZ 696 have been published showing a beneficial effect in the context of various comorbidities, such as renal insufficiency, diabetes and hypotension. Furthermore, new data are available on intravenous iron substitution in chronic heart failure and on the indications for implantable converter defibrillators, cardiac resynchronization therapy and other cardiac devices. Medicinal therapy of acute heart failure is still limited. For patients who cannot be treated with medicinal therapy, mechanical circulatory support, such as extracorporeal membrane oxygenation (ECMO) should be recommended.

Zwitterionic coating assisted by dopamine with metal-phenolic networks loaded on titanium with improved biocompatibility and antibacterial property for artificial heart

“…Heart transplantation, drug therapy and artificial heart implantation are considered to be the main measures to treat heart failure until now ( Crespo-Leiro et al, 2018 ). Due to the serious shortage of heart donors ( Guyette et al, 2016 ; Wang et al, 2022 ), as well as the limitations of drug therapy ( Kresoja et al, 2017 ) and xenotransplantation ( Reardon, 2022 ; Cooper et al, 2022 ; Griffith et al, 2022 ), artificial heart has actually become the most potential way to treat heart failure ( Almond et al, 2013 ; Goldstein et al, 2019 ; Kormos et al, 2019 ; Mehra et al, 2019 ; Shah et al, 2022 ). Inevitably, patients implanted with artificial hearts will face some serious infection problems ( Kirklin et al, 2017 ; Chouirfa et al, 2019 ; Mulzer et al, 2020 ; Zhou et al, 2021 ), for example, the massive reproduction of bacteria represented by E. coli ( Escherichia coli ) and S. aureus ( Staphylococcus aureus ) on the surface of the implant materials ( Chen et al, 2021 ; Zhu et al, 2022 ).…”